安进 AMGN 深 沪
等待开盘 12-03 09:30:00 美东时间
338.36
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 338.36
- 总市值 1820.38亿
- 52周最高 345.66
- 市盈率 静 44.76
- 换手率 0.00%
- 52周最低 243.78
- 委 比 0.00%
- 总股本 5.38亿
- 历史最高 343.46
- 量 比 0
- 振 幅 0.00%
- 历史最低 -25.919
- 每 手 1
- 风险率 19.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BMO Capital Maintains Outperform on Amgen, Raises Price Target to $372
BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $335 to $372.
49分钟前
Janux Therapeutics暴跌近50%，前列腺癌研究数据存在缺口引发投资者担忧
登录新浪财经APP 搜索【信披】查看更多考评等级 Janux Therapeutics 公司股价周二暴跌近 50%。此前...
今天 00:17
估值飙涨25倍！携带辉瑞与诺和诺德“抢破头”的cAMP技术，这家Biotech开赌IPO
（来源：E药资本界） 今年成立第八年的先为达生物，迫不及待想去港交所敲钟。 2024年11月，先为达生物完成了第7轮IPO前（D轮）融资，估值达到约...
12-02 19:28
Biocon Biologics Secures Market Entry for Denosumab Biosimilars in Europe
The latest announcement is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Bio...
12-02 12:23
查理·芒格最后的灿烂岁月：他挥出了一记重拳，且大获全胜
本文来自：聪明投资者 “大家都知道芒格先生一生投资的股票很少，但是他一辈子在坚持研究。在99岁时，他又发现了一只很有趣的股票，有点‘政治不正确’，被极度地错误...
11-28 16:13
Riding the gravy train: Dividend stocks carving out 20%+ returns
The 2025 trading year has been largely positive for stocks, despite a November pullback that saw increased selling pressures. Major market averages remain firmly in the green for the year, with the Do...
11-27 00:03
Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.0% ...
11-26 04:00
Avantor® Receives 2025 Edison Patent Award for Sustainable Viral Inactivation Technology
Research & Development Council of New Jersey honors Avantor for developing a biodegradable detergent solution that advances safe, sustainable biomanufacturing RADNOR, Pa., Nov. 25, 2025 /PRN...
11-25 21:05
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
The European Commission has approved Teva's biosimilars PONLIMSI and DEGEVMA, expanding access to bone health treatments across Europe. These approvals highlight Teva's commitment to broadening biosimilar access and advancing its growth strategy. PONLIMSI is a biosimilar to Prolia® for osteoporosis and bone conditions, while DEGEVMA is a biosimilar to Xgeva® for bone complications in cancer and giant cell tumors. Both medications target RANKL to ...
11-25 13:10
